Search results
Showing 1351 to 1400 of 3041 results for all
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)
Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
In development Reference number: GID-TA11559 Expected publication date: TBC
This indicator covers the percentage of patients with diabetes without moderate or severe frailty, on the register, in whom the last IFCC-HbA1c is 58 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM157
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.
Fruquintinib for previously treated metastatic colorectal cancer (TA1079)
Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.
This indicator covers the percentage of patients with diabetes who have a record of an albumin creatinine ratio (ACR) test in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This asthma pathway signposts recommendations and resources from the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and Scottish Intercollegiate Guidelines Network (SIGN) on diagnosing, monitoring and managing asthma in adults, young people and children, so you can see what guidance is available all in one place.
Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
We are listening to your views on this Technology appraisal guidance. Comments close 9 January 2026.
Pharmalgen for the treatment of bee and wasp venom allergy: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 9 January 2026.
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)
Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.
the menopause is called anastrozole. However, this may not be suitable for all women; for example, women who have severe osteoporosis....
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.
Evidence-based recommendations on autologous chondrocyte implantation using chondrosphere (Spherox) for treating symptomatic articular cartilage defects of the knee in adults.
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults.
Late-stage assessment (LSA) guidance on intermittent urethral catheters for chronic incomplete bladder emptying in adults.
Myocardial infarction: medication for MI more than 12 months ago (IND126)
This indicator covers the percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), aspirin (or clopidogrel, or anticoagulant drug therapy) and a statin, and a beta-blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM80
Myocardial infarction: medication for MI in preceding 12 months (IND125)
This indicator covers the percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), dual antiplatelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM79
Smoking: smoking status of people with long-term conditions (IND156)
This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD or asthma, whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM126
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM97.
Smoking: smoking status for people with long-term conditions (IND97)
This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM38
In development Reference number: GID-HST10054 Expected publication date: 20 February 2026
Minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones (MIB138)
NICE has developed a medtech innovation briefing (MIB) on minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones .
NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.
In development Reference number: GID-TA10977 Expected publication date: TBC
Obinutuzumab with immunosuppressive therapies for treating lupus nephritis [ID6420]
In development Reference number: GID-TA11478 Expected publication date: 11 March 2026
Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)
Advice on the use of Cellvizio confocal endomicroscopy system (CLS) for characterising pancreatic cysts to aid local decision-making
Gemcitabine for the treatment of metastatic breast cancer (TA116)
Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults.
Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making
and support for people living with dementia and their carers c NICE 2018. All rights reserved. Subject to Notice of rights. Last updated...
This quality standard covers the initial management of self-harm and the provision of longer-term support for children and young people (aged 8 to 18) and adults (aged 18 and over) who self-harm. It describes high-quality care in priority areas for improvement.
View quality statements for QS34Show all sections
Sections for QS34
- Quality statements
- Quality statement 1: Compassion, respect and dignity
- Quality statement 2: Initial assessments
- Quality statement 3: Psychosocial assessments
- Quality statement 4: Observation
- Quality statement 5: Safe physical environments
- Quality statement 6: Care plans
- Quality statement 7: Psychological interventions
NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .
Percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation (IPG427)
Evidence-based recommendations on percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation. This involves using a probe attached to a balloon catheter to freeze tissue in one of the chambers on the left side of the heart.
View recommendations for IPG427Show all sections
Sections for IPG427
LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)
NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home
Evidence-based recommendations on brexucabtagene autoleucel (Tecartus) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over.
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults
This process guide provides an overview of the key principles used for developing NICE decision aids. It ensures that robust, quality-assured decision aids for people using and providing health and social care services are developed in an open, transparent and timely way, with appropriate input from key groups
This indicator covers the percentage of patients with asthma on the register with a risk factor for poor outcomes, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control, a recording of the number of exacerbations, an assessment of inhaler technique and a written personalised action plan. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Ex-situ machine perfusion for extracorporeal preservation of livers for transplantation (IPG636)
Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of livers for transplantation in people of all ages. This involves using a machine to give an oxygenated solution to the donor liver until it is transplanted.
View recommendations for IPG636Show all sections
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (HTG388)
Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions.